Metabolic Signature Identifies Novel Targets for Drug Resistance in Multiple Myeloma

Overview

Journal Cancer Res

Specialty Oncology

Date 2015 Mar 15

PMID 25769724

Citations 120

Authors

Patricia Maiso

Daisy Huynh

Michele Moschetta

Antonio Sacco

Yosra Aljawai

Yuji Mishima

John M Asara

Aldo M Roccaro

Alec C Kimmelman

Irene M Ghobrial

Affiliations

Soon will be listed here.

Abstract

Drug resistance remains a major clinical challenge for cancer treatment. Multiple myeloma is an incurable plasma cell cancer selectively localized in the bone marrow. The main cause of resistance in myeloma is the minimal residual disease cells that are resistant to the original therapy, including bortezomib treatment and high-dose melphalan in stem cell transplant. In this study, we demonstrate that altered tumor cell metabolism is essential for the regulation of drug resistance in multiple myeloma cells. We show the unprecedented role of the metabolic phenotype in inducing drug resistance through LDHA and HIF1A in multiple myeloma, and that specific inhibition of LDHA and HIF1A can restore sensitivity to therapeutic agents such as bortezomib and can also inhibit tumor growth induced by altered metabolism. Knockdown of LDHA can restore sensitivity of bortezomib resistance cell lines while gain-of-function studies using LDHA or HIF1A induced resistance in bortezomib-sensitive cell lines. Taken together, these data suggest that HIF1A and LDHA are important targets for hypoxia-driven drug resistance. Novel drugs that regulate metabolic pathways in multiple myeloma, specifically targeting LDHA, can be beneficial to inhibit tumor growth and overcome drug resistance.

Citing Articles

Inhibition of CDC27 O-GlcNAcylation coordinates the antitumor efficacy in multiple myeloma through the autophagy-lysosome pathway.

Wu H, Qin R, Li W, Liu J, Deng C, Zheng Z Acta Pharmacol Sin. 2025; .

PMID: 39984622 DOI: 10.1038/s41401-025-01500-2.

Metabolic reprogramming induced by PSMA4 overexpression facilitates bortezomib resistance in multiple myeloma.

Yu H, Wu C, He J, Zhang Y, Cao Q, Lan H Ann Hematol. 2025; .

PMID: 39755751 DOI: 10.1007/s00277-024-06163-3.

Acquired Bortezomib Resistance in Multiple Myeloma: From Mechanisms to Strategy.

Li F, Liu J, Fu Y Curr Treat Options Oncol. 2024; 25(11):1354-1365.

PMID: 39432172 DOI: 10.1007/s11864-024-01273-6.

Metabolic Function and Therapeutic Potential of CD147 for Hematological Malignancies: An Overview.

Spinello I, Labbaye C, Saulle E Int J Mol Sci. 2024; 25(17).

PMID: 39273126 PMC: 11395103. DOI: 10.3390/ijms25179178.

Unraveling the complexity of drug resistance mechanisms to SINE, T cell-engaging therapies and CELMoDs in multiple myeloma: a comprehensive review.

Schutt J, Brinkert K, Plis A, Schenk T, Brioli A Cancer Drug Resist. 2024; 7:26.

PMID: 39050883 PMC: 11267153. DOI: 10.20517/cdr.2024.39.

References

Maiso P, Carvajal-Vergara X, Ocio E, Lopez-Perez R, Mateo G, Gutierrez N . The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res. 2006; 66(11):5781-9. DOI: 10.1158/0008-5472.CAN-05-4186. View

Warburg O . On respiratory impairment in cancer cells. Science. 1956; 124(3215):269-70. View

Schaefer C, Anthony K, Krupa S, Buchoff J, Day M, Hannay T . PID: the Pathway Interaction Database. Nucleic Acids Res. 2008; 37(Database issue):D674-9. PMC: 2686461. DOI: 10.1093/nar/gkn653. View

Hamanaka R, Chandel N . Targeting glucose metabolism for cancer therapy. J Exp Med. 2012; 209(2):211-5. PMC: 3280882. DOI: 10.1084/jem.20120162. View

Gatenby R, Gillies R . Why do cancers have high aerobic glycolysis?. Nat Rev Cancer. 2004; 4(11):891-9. DOI: 10.1038/nrc1478. View

Erler J, Bennewith K, Nicolau M, Dornhofer N, Kong C, Le Q . Lysyl oxidase is essential for hypoxia-induced metastasis. Nature. 2006; 440(7088):1222-6. DOI: 10.1038/nature04695. View

Kurtoglu M, Gao N, Shang J, Maher J, Lehrman M, Wangpaichitr M . Under normoxia, 2-deoxy-D-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation. Mol Cancer Ther. 2007; 6(11):3049-58. DOI: 10.1158/1535-7163.MCT-07-0310. View

Zhao Y, Liu H, Liu Z, Ding Y, LeDoux S, Wilson G . Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism. Cancer Res. 2011; 71(13):4585-97. PMC: 3129363. DOI: 10.1158/0008-5472.CAN-11-0127. View

Ader I, Brizuela L, Bouquerel P, Malavaud B, Cuvillier O . Sphingosine kinase 1: a new modulator of hypoxia inducible factor 1alpha during hypoxia in human cancer cells. Cancer Res. 2008; 68(20):8635-42. DOI: 10.1158/0008-5472.CAN-08-0917. View

10.

Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng W, Roels S . Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood. 2006; 109(8):3177-88. DOI: 10.1182/blood-2006-09-044974. View

11.

Maher J, Krishan A, Lampidis T . Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-D-glucose in tumor cells treated under hypoxic vs aerobic conditions. Cancer Chemother Pharmacol. 2003; 53(2):116-22. DOI: 10.1007/s00280-003-0724-7. View

12.

Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M . HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001; 292(5516):464-8. DOI: 10.1126/science.1059817. View

13.

Zhang Y, Li M, Yao Q, Chen C . Recent advances in tumor hypoxia: tumor progression, molecular mechanisms, and therapeutic implications. Med Sci Monit. 2007; 13(10):RA175-80. View

14.

Wheaton W, Chandel N . Hypoxia. 2. Hypoxia regulates cellular metabolism. Am J Physiol Cell Physiol. 2010; 300(3):C385-93. PMC: 3063979. DOI: 10.1152/ajpcell.00485.2010. View

15.

Chi J, Wang Z, Nuyten D, Rodriguez E, Schaner M, Salim A . Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med. 2006; 3(3):e47. PMC: 1334226. DOI: 10.1371/journal.pmed.0030047. View

16.

Liu Y, Cao Y, Zhang W, Bergmeier S, Qian Y, Akbar H . A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol Cancer Ther. 2012; 11(8):1672-82. DOI: 10.1158/1535-7163.MCT-12-0131. View

17.

Cao X, Fang L, Gibbs S, Huang Y, Dai Z, Wen P . Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia. Cancer Chemother Pharmacol. 2006; 59(4):495-505. DOI: 10.1007/s00280-006-0291-9. View

18.

Macheda M, Rogers S, Best J . Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol. 2004; 202(3):654-62. DOI: 10.1002/jcp.20166. View

19.

Erler J, Bennewith K, Cox T, Lang G, Bird D, Koong A . Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell. 2008; 15(1):35-44. PMC: 3050620. DOI: 10.1016/j.ccr.2008.11.012. View

20.

Monti E, Gariboldi M . HIF-1 as a target for cancer chemotherapy, chemosensitization and chemoprevention. Curr Mol Pharmacol. 2010; 4(1):62-77. DOI: 10.2174/1874467211104010062. View